The strongest sector yesterday was Healthcare. This defensive group has recently lagged the SPY due to a combination of regulatory and political uncertainty—most notably around drug pricing reforms, new import tariffs, and disruptive leadership changes—combined with operational pressures from rising reimbursement costs, clinical trial setbacks, and margin erosion at insurers. Investor sentiment has been further weighed down by years of underperformance, steep valuation discounts relative to the broader market, and sustained fund outflows, leaving the sector vulnerable to policy shocks but potentially primed for a rebound if political clarity and positive clinical developments emerge.
The U.S. pharmaceutical supply chain remains heavily dependent on imports, with more than USD 260 billion annually in combined finished drug and raw material/API imports—primarily from Europe, India, and China—against roughly USD 100 billion in exports, resulting in a persistent trade deficit. While much of the final dosage manufacturing takes place domestically, the upstream pipeline is highly reliant on foreign-sourced APIs, 88% of which are imported, leaving domestic capacity insufficient to meet total demand.
Recently implemented and proposed import tariffs of around 25% pose a significant risk of raising landed costs, given that roughly half of U.S. pharmaceutical consumption is sourced from abroad. Such measures could add up to USD 65 billion in annual costs, with even partial pass-through translating into more than USD 43 billion in extra yearly expenses for U.S. consumers—via higher drug prices, insurance premiums, and pressure on public health budgets. Beyond affordability concerns, these dynamics could lead to formulary restrictions, treatment delays, and increased reliance on older generics, creating both revenue opportunities for certain manufacturers and margin/demand pressures in more price-sensitive segments.
Higher insider buying in Healthcare stocks has been observed recently, here some examples:
Ticker Buyers Vol(USD) Week Notes
BDX 1 1005742 33/2025 Gregory Hayes (Director) HSIC 1 670800 33/2025 William K. Daniel (Director) TNDM 2 251722 33/2025 Leigh Vosseller (EVP & CFO); … CNC 1 490365 32/2025 Sarah London (CEO) CRSP 1 1140600 32/2025 Douglas A. Treco (Director) LLY 1 127913 32/2025 Jamere Jackson (Director) FTV 1 1001739 32/2025 Okerstrom Mark D (CFO) MOH 1 1559365 32/2025 James Woys (COO) NEO 1 112322 32/2025 Jeffrey Scott Sherman (CFO) OPK 1 891000 32/2025 Phillip Frost (CEO & Chairman) TFX 4 576215 32/2025 Liam Kelly (Chairman, President & CEO); … VRTX 2 5844184 32/2025 Reshma Kewalramani (CEO & President); … CVS 1 2001000 8/2025 Director Mike Mahoney UNH 2 30000000 20/2025 CEO Stephen J. Hemsley (25M)
Market Outlook: The S&P 500 had a weak session with a selling flow event into the close. This comes as no surprise, with traders and investors squarely focused on today’s PCE data release, scheduled one hour before the market opens. Given an unusual rise in short-term volatility, the SP500 Indicator suggests that a breakout move is likely today, most probably triggered by the PCE print.
Expectations: • Core PCE YoY: 2.7% • Core PCE MoM: 0.2%–0.3% • Fed setup: No rate cut in July (done). Markets currently lean toward a 25 bp cut in September if disinflation continues and growth moderates.
Anticipated Scenarios:
SUPER BULL - Soft PCE (≤0.1% MoM core, YoY near 2.6%) – A clear disinflation surprise would make a September 25 bp cut highly likely, with the Fed adopting a dovish tone on inflation progress. Yields would decline, the dollar would weaken, and the S&P 500 could rise by around 1–1.8%, led by rate-sensitive growth stocks, small caps, REITs, and a healthcare rebound.
BULL - In-line PCE (0.2–0.25% MoM core, YoY 2.7%) – Keeps a September cut firmly in play but with “data-dependent” guidance. Rates and FX remain little changed, and the S&P could post modest gains of 0–0.5%, with steady mega-cap growth and some rotation into cyclicals if growth data confirms.
BEAR - Hot PCE (0.3% MoM core, sticky services) – Reduces September cut odds, prompting a more patient Fed stance. Short-term yields rise, the dollar strengthens, and the S&P could fall 1–2%, with defensive sectors outperforming and growth names pressured by higher real yields.
SUPER BEAR - Much Hotter PCE (≥0.4% MoM core, YoY re-accelerates) – Likely removes September cuts from consideration, shifting expectations toward November/December or reviving “higher for longer” rhetoric. Short-term yields and the dollar surge, financial conditions tighten, and the S&P could drop 2–3.5%, with sharp declines in long-duration growth stocks and some cushioning from value and energy sectors.
Be prepared!